Read the Medication Guide provided by your pharmacist before you start using leuprolide and each time you get a refill. If you have any questions, ask your doctor or pharmacist. This medication is ...

SCHAUMBURG, Ill., June 02, 2025--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Leuprolide Acetate ...

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX), an integrated essential medicines company, announced Wednesday that it has received Abbreviated New Drug Application or ANDA approval from the U.S.

Combined mTOR and AKT inhibition in renal cell carcinoma (RCC). Background: Leuprolide acetate is a synthetic analog of gonadotropin hormone-releasing hormone (GnRH-a) that reduces serum testosterone ...

Please provide your email address to receive an email when new articles are posted on . A subcutaneous injection of leuprolide acetate every 6 months was effective and well tolerated in treating ...

Male patient talking to doctor. CRFS after relugolix was not significantly different compared with leuprolide in men with advanced prostate cancer and metastatic disease. Castration resistance-free ...

(HealthDay)—For men with advanced prostate cancer, the oral gonadotropin-releasing hormone (GnRH) antagonist relugolix maintains testosterone suppression compared with the GnRH agonist leuprolide, ...

Cipla is introducing leuprolide acetate injection depot, 22.5 mg, which is the generic of AbbVie’s Lupron Depot. It is indicated for palliative treatment of advanced prostate cancer. Leuprolide ...

The Food and Drug Administration has cleared Amneal’s leuprolide acetate for injection, which is indicated in the palliative treatment of advanced prostatic cancer. “We are making tremendous progress ...

Data suggest that oral formulations of leuprolide developed utilizing Enteris' Peptelligence® platform successfully deliver meaningful circulating drug concentrations and achieve hormonal suppressive ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the ...